NCT07437300Not yet recruiting
Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma.
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The underlying hypothesis of the study is that melanoma patients treated with immunotherapy, whether in an adjuvant or curative setting, who consume more fiber would respond better to immunotherapy: either no recurrence in the case of adjuvant treatments, or no progression (disease stability, partial or complete response) in the case of curative treatments. The primary objective is to evaluate the association between total dietary fiber intake quantified using the FiberTAG questionnaire and response to immunotherapy treatment in patients treated for melanoma in a curative or adjuvant setting
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 20 Feb 2026
- Start date
- Feb 2026
- Primary completion date
- May 2026
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Melanoma
- NCT number
- NCT07437300
What you commit to
- Study type: Observational
- Planned participants: 60
- From Feb 2026 to the primary completion date, May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recurrence of the disease within 6 months or less after a first line of adjuvant treatment with immunotherapy for 1 year
- Immunotherapy as a third line of treatment in metastatic situations
- Squamous cell carcinoma or basal cell carcinoma treated with immunotherapy
- Immunotherapy in a neoadjuvant situation
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all protected persons: pregnant women, women in labor, breastfeeding mothers, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8, persons admitted to a health or social care institution for purposes other than research, minors, persons subject to legal protection measures or unable to give their consent). persons subject to legal protection measures)
Other illness
- Inability to complete the FiberTAG and GPAQ questionnaires (advanced neurocognitive disorders, memory loss, etc.)
Other
- Inclusion in an interventional clinical study
Who the study is looking for
- Melanoma treated with curative immunotherapy (IPILIMUMAB + NIVOLUMAB or NIVOLUMAB or PEMBROLIZUMAB or NIVOLUMAB + RELATLIMAB) or adjuvant immunotherapy (NIVOLUMAB or PEMBROLIZUMAB)
- Patients monitored and treated at the dermatology day hospital at Grenoble Alpes University Hospital
- Obtaining the patient's consent
- Start of immunotherapy less than or equal to 1 year at the time of inclusion
- Subject affiliated with social security system
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.